Fidelity Management & Research Co recently announced the acquisition of new stake in Keros Therapeutics Inc. (NASDAQ:KROS). The institutional investor has increased its shareholding in the Healthcare company by 6.55% to 3.84 million shares with purchase of 0.24 million shares. This fresh investment now brings its stake to 13.93% valued currently at $184.17 million. In addition, Alkeon Capital Management LLC raised its holdings by 32389.0 to 1.21 million shares. And BlackRock Fund Advisors has lifted its position by 4.78% or 51075.0 shares – to 1.12 million shares.
With over 0.25 million Keros Therapeutics Inc. (KROS) shares trading Tuesday and a closing price of $49.86 on the day, the dollar volume was approximately $12.59 million. The shares have shown a positive half year performance of 79.35% and its price on 01/17/23 gained nearly 1.42%. Currently, there are 25.55M common shares owned by the public and among those 24.81M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 6 analysts who have offered their price forecasts for KROS have a consensus price objective of $96.67. The analysts have set the share’s price value over the next 12 months at a high of $120.00 and a low of $75.00. The average price target is 48.42% above its recent price level and an upside to the estimated low will see the stock gain 33.52% over that period. But an upside of 58.45% will see the stock hit the forecast high price target while median target price for the stock is $100.00.
Insiders at the company have transacted a total of 44 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 11 of these insider trades were purchases, accounting for 88,792 shares. Insider sales of the common stock occurred on 33 occasions, with total insider shares sold totaling 95,920 shares.
The top 3 mutual fund holders in Keros Therapeutics Inc. are SPDR S&P Biotech ETF, Fidelity Advisor Series VII – Bio, and ACAP Strategic Fund. SPDR S&P Biotech ETF owns 0.65 million shares of the company’s stock, all valued at over $31.07 million. The company bought an additional 2608.0 shares recently to bring their total holdings to about 2.35% of the shares outstanding. Fidelity Advisor Series VII – Bio sold -0.14 million shares to see its total holdings shrink to 0.55 million shares valued at over $26.2 million and representing 1.98% of the shares outstanding. ACAP Strategic Fund bought 48761.0 shares to bring its total holdings to over 0.54 million shares at a value of $26.09 million. ACAP Strategic Fund now owns shares totaling to 1.97% of the shares outstanding.
Shares of Keros Therapeutics Inc. (NASDAQ: KROS) opened at $47.61, down -$1.55 from a prior closing price of $49.16. However, the script later moved the day high at 50.08, up 1.42%. The company’s stock has a 5-day price change of 7.48% and 13.50% over the past three months. KROS shares are trading 3.83% year to date (YTD), with the 12-month market performance down to -0.18% lower. It has a 12-month low price of $24.38 and touched a high of $68.29 over the same period. KROS has an average intraday trading volume of 193.93K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.73%, 4.35%, and 18.49% respectively.
Institutional ownership of Keros Therapeutics Inc. (NASDAQ: KROS) shares accounts for 85.30% of the company’s 25.55M shares outstanding. Mutual fund holders own 24.76%, while other institutional holders and individual stakeholders account for 34.99% and 23.27% respectively.
It has a market capitalization of $1.36B. The earnings-per-share (ttm) stands at -$3.36. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.52% over the week and 5.49% over the month.
Analysts forecast that Keros Therapeutics Inc. (KROS) will achieve an EPS of -$1.23 for the current quarter, -$1.22 for the next quarter and -$4.86 for 2023. The lowest estimate earnings-per-share for the quarter is -$1.32 while analysts give the company a high EPS estimate of -$1.09. Comparatively, EPS for the current quarter was -$0.87 a year ago. Earnings per share for the fiscal year are expected to increase by 14.30%, and -9.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate Keros Therapeutics Inc. (KROS) as a “Strong Buy” at a consensus score of 1.50. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the KROS, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on October 18, 2022, with the firm’s price target at $100. BTIG Research coverage for the Keros Therapeutics Inc. (KROS) stock in a research note released on July 26, 2022 offered a Buy rating with a price target of $80. H.C. Wainwright was of a view on December 08, 2020 that the stock is Buy, while SVB Leerink gave the stock Outperform rating on May 04, 2020, issuing a price target of $42. Piper Sandler on their part issued Overweight rating on May 04, 2020.